| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Date of Report (Date of earliest event reported): November 16, 2026 |
| 21 Oct 2026 | DEFINITIVE ADDITIONAL MATERIALS |
| 21 Oct 2026 | DEFINITIVE PROXY STATEMENT |
| 06 Oct 2026 | PRELIMINARY PROXY STATEMENT |
| 18 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
As previously disclosed, on August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) convened its annual meeting of stockholders of the Company (the “Annual Meeting”). At the Annual Meeting, the Company did not receive a sufficient number of... |
| 10 Sep 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 02 Sep 2026 |
8-K: Regulation FD Disclosure
Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's cur... |
| 19 Aug 2026 | DEFINITIVE ADDITIONAL MATERIALS |
| 19 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On August 18, 2026, 20/20 Biolabs, Inc. (the “Company”) held an annual meeting of stockholders of the Company (the “Annual Meeting”) via live webcast. Holders of shares of the Company’s common stock at the close of business on June 22, 2... |
| 17 Aug 2026 | PROSPECTUS SUPPLEMENT |
| 17 Aug 2026 | PROSPECTUS SUPPLEMENT |
| 17 Aug 2026 |
8-K: Results of Operations and Financial Condition
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level |
| 14 Aug 2026 | QUARTERLY REPORT |
| 05 Aug 2026 |
8-K: Regulation FD Disclosure
Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's cur... |
| 22 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule
This Standstill Agreement (this “Agreement”) is entered into as of July 16, 2026 (the “Effective Date”) by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and 20/20 Biolabs, Inc., a Delaware corpora... |
| 01 Jul 2026 |
8-K: Regulation FD Disclosure
Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's cur... |
| 23 Jun 2026 | DEFINITIVE ADDITIONAL MATERIALS |
| 23 Jun 2026 | Proxy statement: annual meeting on August 18, 2026 |
| 01 Jun 2026 | PRELIMINARY PROXY STATEMENT |
| 26 May 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
This Amendment No. 1 to Amended and Restated Bylaws (this “Amendment”) of 20/20 Biolabs, Inc., a Delaware corporation (formerly 20/20 GeneSystems, Inc.) (the “Corporation”), is effective as of May 19, 2026 (the “Effective Date”). |
Loading...